Your search returned 3 results.

Results
	1.	Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis. [electronic resource] by Kongnakorn, Thitima Sterchele, James A Salvador, Christopher G Getsios, Denis Mwamburi, Mkaya Producer: 20140414 In: ClinicoEconomics and outcomes research : CEOR vol. 6 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis. [electronic resource] by Nordstrom, Beth L Knopf, Kevin B Teltsch, Dana Y Engle, Robert Beygi, Hooman Sterchele, James A Producer: 20150715 In: Leukemia & lymphoma vol. 55 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. [electronic resource] by Kolibaba, Kathryn S Sterchele, James A Joshi, Avani D Forsyth, Michael Alwon, Erin Beygi, Hooman Kennealey, Gerard T Producer: 20130605 In: Therapeutic advances in hematology vol. 4 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)